# Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

> **NCT00303940** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 26 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors
- Childhood Germ Cell Tumor
- Kidney Cancer
- Liver Cancer
- Neuroblastoma
- Ovarian Cancer
- Sarcoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** carboplatin
- **DRUG:** talabostat mesylate
- **DRUG:** temozolomide
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00303940
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2010-02
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303940, "Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00303940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*